LBF20303PG05

Revision as of 21:00, 14 April 2010 by Editor (talk | contribs)
LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



Prostaglandin D3
LBF20303PG05.png
Structural Information
9α,15S-dihydroxy-11-oxo-prosta-5Z,13E,17Z-trien-1-oic acid
  • Prostaglandin D3
Formula C20H30O5
Exact Mass 350.20932407
Average Mass 350.4492
SMILES C(=CC[C@@H](O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC
Physicochemical Information
PGD3 is produced by the metabolism of EPA via the cyclooxygenase pathway. Kulkarni_PS et al.
PGD3 has almost same ability to decrease systemic blood pressure in rats and to decrease intraocular pressure in rabbits. Bundy_GL et al. Goh_Y et al. Kulkarni_PS et al. However, it is 3 to 5 times more potent than PGD2 in the inhibition of ADP-induced human platelet aggregation.
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20303PG05 See above. Bundy_GL et al. 1983
n.a. LBF20303PG05 See above. Goh_Y et al. 1988
n.a. LBF20303PG05 See above. Herschman_HR 1996
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1987
n.a. LBF20303PG05 See above. Kulkarni_PS et al. 1985
n.a. LBF20303PG05 See above. Smith_WL et al. 1996